Arrowhead Pharmaceuticals Ownership | Who Owns Arrowhead Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Arrowhead Pharmaceuticals Ownership Summary


Arrowhead Pharmaceuticals is owned by 79.91% institutional investors, 4.71% insiders, and 15.38% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 13.51% of ARWR shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 6.28% of its assets in Arrowhead Pharmaceuticals shares.

ARWR Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockArrowhead Pharmaceuticals79.91%4.71%15.38%
SectorHealthcare Stocks 57.43%9.41%33.16%
IndustryBiotech Stocks 69.02%8.92%22.06%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de16.18M13.51%$304.15M
Blackrock15.68M12.72%$407.61M
Vanguard group12.18M10.17%$229.06M
Avoro capital advisors11.11M9.28%$208.89M
State street6.02M4.82%$113.11M
Slate path capital lp5.23M4.37%$98.36M
Fmr5.10M4.26%$95.90M
Geode capital management2.95M2.47%$55.57M
Siren2.90M2.42%$54.55M
T. rowe price investment management2.51M2.09%$47.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Aquilo capital management707.59K20.06%$13.30M
Western financial corp/ca820.24K8.47%$15.42M
Avoro capital advisors11.11M2.95%$208.89M
Siren2.90M2.41%$54.55M
Hound partners325.52K2.35%$6.12M
Slate path capital lp5.23M1.78%$98.36M
Privium fund management b.v.380.59K1.62%$7.16M
M28 capital management lp67.40K1.24%$1.27M
Altium capital management lp230.26K1.23%$4.33M
Johnson & johnson247.60K1.21%$4.65M

Top Buyers

HolderShares% AssetsChange
Avoro capital advisors11.11M2.95%2.22M
Norges bank2.05M0.01%2.05M
Ubs group1.31M0.00%863.82K
Morgan stanley1.82M0.00%679.41K
Farallon capital management628.80K0.06%628.80K

Top Sellers

HolderShares% AssetsChange
T. rowe price investment management2.51M0.03%-1.07M
Fmr5.10M0.01%-966.49K
Rokos capital management llp---939.98K
Orbimed advisors---739.65K
E. ohman j:or asset management ab---714.21K

New Positions

HolderShares% AssetsChangeValue
Norges bank2.05M0.01%2.05M$38.62M
Farallon capital management628.80K0.06%628.80K$11.82M
Integral health asset management275.00K0.44%275.00K$5.17M
Wealthfront advisers109.57K0.01%109.57K$2.73M
Marshall wace, llp86.63K0.00%86.63K$1.63M

Sold Out

HolderChange
Toronto dominion bank-3.00
Financial gravity asset management-4.00
Innealta capital-11.00
Riggs asset managment-14.00
Bell investment advisors-19.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20242851.42%99,767,6504.15%791.25%1337.26%88-3.30%
Sep 30, 2024278-1.77%95,591,794-2.21%761.22%124-8.15%897.23%
Jun 30, 2024282-1.40%97,756,3002.92%791.34%135-7.53%827.89%
Mar 31, 20242861.06%94,985,78622.73%771.48%14618.70%76-19.15%
Dec 31, 20232839.69%77,395,4775.41%721.54%1237.89%94-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF7.92M6.28%4.30K
iShares Core S&P Mid-Cap ETF4.05M3.25%13.43K
Vanguard Total Stock Mkt Idx Inv3.70M2.96%36.42K
iShares Russell 2000 ETF3.10M2.46%-60.76K
Vanguard Small Cap Index3.02M2.41%5.38K
Vanguard Institutional Extnd Mkt Idx Tr1.89M1.51%519.00
Vanguard Small Cap Growth Index Inv1.71M1.36%-4.62K
SPDR® S&P Biotech ETF1.45M1.15%10.96K
Fidelity Growth Compy Commingled Pl S1.41M1.13%47.16K
Fidelity Growth Compy Commingled Pl O1.21M0.98%127.90K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 03, 2025Anzalone Christopher Richard Chief Executive OfficerSell$3.01M
Mar 04, 2025Anzalone Christopher Richard Chief Executive OfficerSell$2.27M
Jan 23, 2025OLUKOTUN ADEOYE Y-Sell$20.14K
Jan 06, 2025Hamilton James C Chief Discovery/Trans MedicineSell$220.63K
Jan 06, 2025Hamilton James C Chief Discovery/Trans MedicineSell$428.20K

Insider Transactions Trends


DateBuySell
2025 Q1-13
2024 Q4-10
2024 Q3-1
2024 Q2-2
2024 Q1337

ARWR Ownership FAQ


Who Owns Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals shareholders are primarily institutional investors at 79.91%, followed by 4.71% insiders and 15.38% retail investors. The average institutional ownership in Arrowhead Pharmaceuticals's industry, Biotech Stocks , is 69.02%, which Arrowhead Pharmaceuticals exceeds.

Who owns the most shares of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (16.18M shares, 13.51%), Blackrock (15.68M shares, 12.72%), and Vanguard group (12.18M shares, 10.17%). Together, they hold 36.40% of Arrowhead Pharmaceuticals’s total shares outstanding.

Does Blackrock own Arrowhead Pharmaceuticals?

Yes, BlackRock owns 12.72% of Arrowhead Pharmaceuticals, totaling 15.68M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 407.61M$. In the last quarter, BlackRock increased its holdings by 336.57K shares, a 2.19% change.

Who is Arrowhead Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Aquilo capital management is Arrowhead Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 20.06% of its assets in 707.59K Arrowhead Pharmaceuticals shares, valued at 13.3M$.

Who is the top mutual fund holder of Arrowhead Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Arrowhead Pharmaceuticals shares, with 6.28% of its total shares outstanding invested in 7.92M Arrowhead Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools